Target intelligence / Profile preview

Creatine kinase, mitochondrial 1B (CKMT1B)

Target
CKMT1B
Molecular classification
Enzyme, Mitochondrial creatine kinase isoenzyme, Transferase
01

Overview

Creatine kinase, mitochondrial 1B (CKMT1B) is a mitochondrial enzyme belonging to the creatine kinase family, catalyzing the reversible transfer of phosphate between ATP and creatine to maintain cellular energy homeostasis, particularly in tissues with fluctuating or high energy demands such as brain, muscle, and sperm. CKMT1B is one of two genes (along with CKMT1A) encoding the ubiquitous mitochondrial creatine kinase protein, found as dimers or octamers in the mitochondrial intermembrane space, mediating energy buffering and signal transduction required for cellular processes with rapid energy turnover. CKMT1B is clinically relevant as its overexpression is linked to malignancy and poor prognosis in several cancers, while genomic deletions or low expression are diagnostic or prognostic in auditory dysfunction and gliomas, respectively. Loss of CKMT1B function may contribute to disease states by impairing cellular energy balance and is being studied both as a biomarker and potential therapeutic target.

Other names
CKMT1BCKMTCKMT1CKMT1AMia-CKU-MtCKUMTCKAcidic-type mitochondrial creatine kinaseUbiquitous mitochondrial creatine kinasemia-CKubiquitous mitochondrial creatine kinasecreatine kinase U-type, mitochondrial
02

Mechanism of action

Inhibitors would reduce ATP regeneration via phosphocreatine shuttle; Modulators would affect cellular energy buffering, oxidative phosphorylation coupling, and cell survival in high energy-demanding tissues

03

Biological functions

Energy homeostasisCellular energy transduction (energy buffering)Transfer of high-energy phosphate between ATP and creatine (phosphocreatine system)
04

Disease associations

Cancer (overexpression in certain malignant cancers, poor prognosis association)Neurodegenerative disease (suspected from energy metabolism involvement)Cardiovascular disease (role in tissues with high energy demand)Sensorineural hearing loss (implicated as a biomarker in certain genomic deletions)Male infertility (potential comorbidity in deletion syndromes)
05

Safety considerations

Inhibition or loss could compromise energy homeostasis in high-demand tissues (brain, heart, muscle)Potential oncogenic risk if overexpressed (facilitates high metabolic rates, cancer cell survival)Genetic deletion syndromes may have complex phenotypes including hearing loss and infertility
06

Biomarkers

Lower CKMT1B expression is a prognostic indicator of poor prognosis in lower-grade gliomaIncluded in marker panels for sensorineural hearing loss when genomic deletions occur

Beyond the preview

Go deeper on Creatine kinase, mitochondrial 1B (CKMT1B).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Creatine kinase, mitochondrial 1B (CKMT1B).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call